CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 35 filers reported holding CRISPR THERAPEUTICS AG in Q1 2017. The put-call ratio across all filers is - and the average weighting 1.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $953,000 | +85.4% | 15,649 | +24.7% | 0.01% | +50.0% |
Q3 2019 | $514,000 | -2.5% | 12,545 | +12.5% | 0.00% | 0.0% |
Q2 2019 | $527,000 | +33.4% | 11,151 | +1.1% | 0.00% | +33.3% |
Q1 2019 | $395,000 | +33.0% | 11,034 | +6.0% | 0.00% | 0.0% |
Q4 2018 | $297,000 | -21.8% | 10,406 | +21.7% | 0.00% | 0.0% |
Q3 2018 | $380,000 | +104.3% | 8,551 | +110.9% | 0.00% | +50.0% |
Q2 2018 | $186,000 | 0.0% | 4,054 | 0.0% | 0.00% | 0.0% |
Q1 2018 | $186,000 | +745.5% | 4,054 | +334.0% | 0.00% | – |
Q4 2017 | $22,000 | +100.0% | 934 | +47.3% | 0.00% | – |
Q3 2017 | $11,000 | +450.0% | 634 | +534.0% | 0.00% | – |
Q2 2017 | $2,000 | 0.0% | 100 | 0.0% | 0.00% | – |
Q1 2017 | $2,000 | – | 100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |